Calls the technical structure "aggressively bullish" — the MACD histogram compressing from −1.57 to −0.71 is a coiled spring, not a failure, and waiting for a printed cross means paying 4% more. Wants the desk proactively positioned before the breakout, not after.
Dismisses the cash-conversion worry as a byproduct of tripling revenue and argues the macro rate headwind is immaterial against triple-digit earnings growth; would move to 1.0–1.25x standard the moment the add-triggers fire.
Agrees the trend is constructive — reclaimed 50 SMA, volume-confirmed bounce, RSI recovered from 44 to 54 — but rejects adding before confirmation: risk/reward from $222.27 is only ~4% upside to resistance vs. ~5.5% to the $210 stop.
Also pushes back on trimming into normal noise; the levels that matter are $210 (invalidates the recovery) and $198 (breaks the long-term trend), not the VWMA or 50 SMA.
Doesn't dispute the franchise — normalized net income still +101% YoY — but flags operating cash flow nearly halving sequentially to $24.08B and $25B of new debt issued the same quarter as $19.7B of buybacks as real earnings-quality and leverage-timing risks.
Wants to reduce exposure on a close below the 50 SMA ($214.07), before the $210 stop is even tested, and caps any future add at 1.0x standard until the macro rate and policy overhang clears.
Thesis: The bull case is about the company; the bear case is about the price — and at $222.27 they offset. The fundamental engine is intact and largely unrebutted: Q2 revenue $96.2B (+105.8% YoY), 75% gross margins, normalized net income +101% YoY, TTM operating cash flow ~$134B, and a technically intact 10/50/200 SMA stack with a volume-confirmed bounce off the reclaimed 50 SMA. But the bear landed two punches the bull never disproved: Q2 operating cash flow halved sequentially to $24.08B (~40–45% conversion) even as receivables grew faster than revenue, and the 14.2x forward P/E rests on ~100% forward EPS growth — decelerating to a still-excellent 30–50% pushes the effective multiple to 19–22x on a $5.37T, beta-2.22 name into a regime pricing 96% odds of no 2026 Fed cuts.
Action: hold the current standard allocation — do not add, do not trim. The upgrade path requires any two of: a confirmed MACD crossover with a close above ~$232 on sustained volume; Q3 cash conversion back above ~80% with receivables tracking no faster than revenue; or hyperscaler orders remaining intact — alongside gross margins holding at or above 73%. A close below ~$210 invalidates the recovery thesis; a close below the 200 SMA at ~$198, gross-margin erosion below ~73%, or EPS-growth guidance decelerating meaningfully below ~50% would reprice the effective multiple higher and warrant reassessment toward Underweight/Sell.